BHC Options Flip Signals Sentiment Shift Into Q1 Earnings

Bausch Health Companies Inc. heads into its May 7 Q1 results with the most bullish options read in nearly a year — a sharp contrast to the heavy put positioning that defined most of 2026.

The standout this week is the options pivot. The put/call ratio collapsed to 1.11 on April 28, more than two standard deviations below its 20-day average of 1.74. That's close to the 52-week low of 0.97, set last March 31. For context, BHC's PCR has spent almost every session above 1.67 since mid-March. A single-day swing of that magnitude — from 2.05 on April 27 to 1.11 — points to a meaningful rotation out of puts, or fresh call buying, directly ahead of earnings. The RSI14 reads a neutral 53.74, so this isn't a momentum-chasing move; options traders appear to be repositioning rather than following price.

Short interest tells a less charged story and doesn't argue for urgency in either direction. SI % of free float edged up 4.1% on the week to 2.34% of the float — a gentle rebuild from the monthly lows seen in early April, but well below the 2.5% levels that prevailed in mid-March. Borrowing is essentially free at 0.49% annualised, down 16% over the past month. Availability remains very loose — well above the typical thresholds for squeeze pressure — and has been drifting lower from its 52-week peak of 21.8% utilization back in March. There is no meaningful squeeze setup here. The borrow market is relaxed, and the modest SI drift higher this week looks more like positioning ahead of a binary event than any structural short thesis.

The Street is cautious but not bearish. RBC Capital lowered its target from $10 to $9 on April 27, just two days ago, while maintaining its Sector Perform rating — a modest trim that keeps it neutral rather than triggering a downgrade. Barclays cut to $7 back in February. The consensus mean target lands at $7.57, implying 33.5% upside from the current $5.67 price, though the target cluster reflects the stock's recent weakness rather than fresh conviction. The bull case rests on Solta Medical's 28% year-over-year organic growth and resilient Canadian revenues; the bear case is dominated by a projected 7% revenue decline by 2027, driven partly by IRA headwinds and ongoing international softness — Latin America revenues fell 14% year over year in the most recent period. The EV/EBITDA multiple of 5.9x looks undemanding, and the stock scores in the 77th percentile on EV/EBIT, suggesting some valuation support at current levels.

Ownership is dominated by a small group of large holders with little movement. Paulson & Co. holds 19.6% of shares with no recent change. GoldenTree Asset Management sits at 9.3%, also static. The tightest recent move came from Healthcare of Ontario Pension Plan, which cut its stake by 4.5 million shares in the December quarter, and Nomura, which trimmed by 7 million. The CEO sold roughly $7.3 million in shares on March 2 — a block that included both award-related and discretionary sales — though that was nearly two months ago and the stock has since recovered 13% from its April lows. Insider activity, in aggregate, runs modestly net positive on the 90-day read, at roughly $14.7 million net, largely reflecting award issuances rather than open-market conviction buying.

Prior earnings reactions have been muted. The February 2026 print saw the stock fall 1% on the day and slip 2.4% over the following five sessions. The release immediately before that saw a 1-day decline of 1% followed by a modest five-day recovery. Neither reaction was dramatic, which frames the May 7 event as a catalyst where the magnitude of the move matters as much as the direction — particularly given that the options market just shifted sharply toward calls with the release a week away.

What to watch: whether that options repositioning holds into the May 7 report, and whether the Solta Medical segment can repeat its organic growth performance in what the bears argue is a deteriorating revenue backdrop for the broader business.